AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06925854
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1220
- Registration Number
- NCT06921785
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT06921928
- Locations
- 🇯🇵
Research Site, Koto-ku, Japan
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies.
Phase 1
Recruiting
- Conditions
- Systemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT06916806
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
Not Applicable
Not yet recruiting
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT06909773
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Device: Autoinjector (AI) DeviceDevice: Accessorised Prefilled Syringe (APFS) Device
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT06908577
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT06909253
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.
Not yet recruiting
- Conditions
- Description of SLE Activity in Patients in Routine Practice in the Republic of KazakhstanDescription of the Course of SLE in Patients in the Republic of KazakhstanDescription of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06899633
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1
Recruiting
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06897930
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
Phase 2
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT06897748
- Locations
- 🇷🇺
Research Site, Ulyanovsk, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath